Blog

While the January 2025 FDA guidance suggests PK approaches as starting points, our extensive experience implementing biomarker assays reveals why each validation parameter demands careful scientific consideration. Let’s explore how these distinct approaches come together to form a comprehensive, scientifically sound validation framework. Understanding the Fundamental Distinction The key to understanding biomarker validation lies in…

The January 2025 FDA Biomarker Assay Validation guidance suggests starting with PK validation approaches. However, our extensive experience implementing biomarker assays reveals why sample stability assessment demands a fundamentally different scientific approach. Understanding Traditional Drug Assay Validation In drug concentration assays, stability evaluation follows a straightforward path: analysts prepare spiked control samples and demonstrate accurate…

The January 2025 FDA Biomarker Assay Validation guidance suggests using PK validation approaches as a starting point. However, when it comes to dilutional linearity and parallelism, our extensive implementation experience reveals a fundamental scientific distinction that demands careful consideration. Understanding Traditional Drug Assay Validation In drug concentration assays, dilutional linearity serves as a cornerstone validation…

Introduction The January 2025 FDA Biomarker Assay Validation guidance suggests using PK validation approaches as a starting point. However, our extensive experience shows why quantitative range determination for biomarker assays demands a fundamentally different scientific approach. The Traditional Drug Assay Paradigm In drug concentration assays, establishing quantitative ranges follows a straightforward path: analysts confirm ranges…

Introduction The January 2025 FDA guidance suggests using PK validation approaches as a starting point, but our extensive experience implementing biomarker assays reveals why specificity and selectivity demand fundamentally different scientific approaches. Understanding Traditional Drug Assay Validation In drug concentration assays, specificity, and selectivity are demonstrated through straightforward spike recovery experiments. Specificity evaluates reference standard…

Introduction The January 2025 FDA guidance maintains consistency with previous documents in suggesting biomarker validation should start with approaches used for drug assays. However, our extensive experience in biomarker implementation reveals why accuracy and precision require fundamentally different scientific approaches. Understanding Traditional Drug Assay Validation In drug concentration assays, accuracy and precision benefit from a…

February 5th, 2025, 2:30 PM EST- Editorial Note: We have observed that the January 2025 FDA Biomarker Assay Validation guidance document referenced in this post is currently inaccessible through the provided URL (listed in the reference section at the bottom of this article). This development, while noteworthy, does not impact the scientific principles discussed here….

At Immunologix Laboratories, we provide integrated laboratory and scientific services for drug development by combining advanced laboratory capabilities with translational expertise. Since our founding in 2012, we have built an organization that integrates laboratory services with strategic drug development knowledge through our scientific triad model, where each project team includes a Principal Investigator, Translational Scientist,…